Alector, Inc.
ALEC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001653087
In the last 90 days, Alector, Inc. insiders filed 0 open-market purchases and 3 sales; 140 institutions reported holding it in 13F filings for Q2 2026, worth $183.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alector, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $296.1K in total
- Insiders trading
- 3
- Net value
- −$296.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alector, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wong-Sarad Grace | Principal Accounting Officer | 106,015 | Sep 4, 2026 | 11 |
| Berkley Neil Lindsay | CFO & Chief Business Officer | 350,649 | Sep 4, 2026 | 6 |
| Rosenthal Arnon | Chief Executive Officer | 2,294,600 | Sep 4, 2026 | 7 |
| Desouza Errol B | Director | 98,650 | Jun 17, 2026 | 1 |
| Lavigne Louis J Jr | Director | 128,109 | Jun 17, 2026 | 1 |
| Scheller Richard H | Director | 134,899 | Jun 17, 2026 | 2 |
| Altmeyer Mark | Director | 98,650 | Jun 17, 2026 | 1 |
| Yaffe Kristine | Director | 124,109 | Jun 17, 2026 | 1 |
| Hammond Paula | Director | 103,609 | Jun 17, 2026 | 1 |
| Garofalo Elizabeth A. | Director | 118,650 | Jun 17, 2026 | 1 |
| Kenkare-Mitra Sara | President and Head of R&D | 501,652 | Dec 3, 2025 | 1 |
| Grasso Marc | Chief Financial Officer | 296,072 | Jun 4, 2025 | 0 |
| Romano Gary | Chief Medical Officer | 332,977 | Mar 5, 2025 | 0 |
| Wehner David M. | Director | 115,330 | Jun 12, 2024 | 0 |
| Polaris Venture Partners VI, L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Partners Founders' Fund VI, L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Management Co. VI, L.L.C. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Partners VI (AIV), L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| Polaris Venture Partners VI (AIV-B), L.P. | 10% Owner | 0 | May 31, 2024 | 0 |
| McGuire Terrance | Director, 10% Owner | 10,853,817Indirect | Sep 13, 2023 | 0 |
| Gerngross Tillman U. | Director | 2,644,319 | Jun 15, 2023 | 0 |
| King Robert | Chief Development Officer | 550,871 | Oct 4, 2022 | 0 |
| Suliman Shehnaaz | President and COO | 102,598 | Dec 14, 2021 | 0 |
| Paul Robert | Chief Medical Officer | 234,319 | Aug 11, 2021 | 0 |
| Yu Calvin | Vice President, Finance | 76,686 | Jul 7, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 6, 2023 (view filing) | Dec 4 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −23.8K | $5.56 | −$132.5K | −1.2%2.02M after | |
| Dec 6, 2023 (view filing) | Dec 4 | 2 days | Romano GaryChief Medical Officer | SSale | −5.04K | $5.56 | −$28.0K | −2.4%202.3K after | |
| Dec 6, 2023 (view filing) | Dec 4 | 2 days | Grasso MarcChief Financial Officer | SSale | −4.57K | $5.56 | −$25.4K | −2.9%150.7K after | |
| Dec 6, 2023 (view filing) | Dec 4 | 2 days | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −12.5K | $5.56 | −$69.6K | −3.7%329.0K after | |
| Sep 13, 2023 (view filing)4:33 PM ET | Sep 11 | 2 days | Polaris Venture Partners VI, L.P. and 4 others10% Owner | SSale | −500.0K | $6.00 | −$3.00M | −4.4%10.9M after | Duplicate filing |
| Sep 13, 2023 (view filing) | Sep 11 | 2 days | McGuire TerranceDirector, 10% Owner | SSale | −500.0K | $6.00 | −$3.00M | −4.4%10.9M after | |
| Sep 6, 2023 (view filing) | Sep 5 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −5.65K | $5.19 | −$29.3K | −0.3%1.65M after | |
| Sep 6, 2023 (view filing) | Sep 5 | 1 day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −6.21K | $5.19 | −$32.3K | −3.4%177.9K after | |
| Sep 6, 2023 (view filing) | Sep 5 | 1 day | Romano GaryChief Medical Officer | SSale | −2.77K | $5.19 | −$14.4K | −2.7%99.3K after | |
| Sep 6, 2023 (view filing) | Sep 5 | 1 day | Grasso MarcChief Financial Officer | SSale | −1.11K | $5.19 | −$5.78K | −3.3%32.2K after | |
| Jun 5, 2023 (view filing) | Jun 2 | 3 days | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −4.09K | $6.90 | −$28.2K | −2.2%184.1K after | |
| Jun 5, 2023 (view filing) | Jun 2 | 3 days | Grasso MarcChief Financial Officer | SSale | −1.05K | $6.90 | −$7.25K | −3.1%33.4K after | |
| Jun 5, 2023 (view filing) | Jun 2 | 3 days | Romano GaryChief Medical Officer | SSale | −2.62K | $6.90 | −$18.1K | −2.5%102.1K after | |
| Jun 5, 2023 (view filing) | Jun 2 | 3 days | Rosenthal ArnonChief Executive Officer | SSale | −5.25K | $6.90 | −$36.3K | −0.3%1.65M after | |
| Mar 21, 2023 (view filing) | Mar 17 | 4 days | Rosenthal ArnonChief Executive Officer | SSale | −15.2K | $6.22 | −$94.5K | −0.9%1.66M after | |
| Mar 3, 2023 (view filing) | Dec 2, 2022-Mar 2, 2023 | 91 daysLate | Romano GaryChief Medical Officer | SSale | −5.38K | $8.48 | −$45.6K | −4.9%104.7K after | 2 lots |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Kenkare-Mitra SaraPresident and Head of R&D | SSale | −10.1K | $8.32 | −$84.2K | −5.1%188.2K after | |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Grasso MarcChief Financial Officer | SSale | −1.29K | $8.32 | −$10.7K | −3.6%34.4K after | |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −5.85K | $8.32 | −$48.7K | −0.4%1.63M after | |
| Sep 7, 2022 (view filing) | Sep 2 | 5 days | Romano GaryChief Medical Officer | SSale | −2.18K | $10.62 | −$23.1K | −2.4%90.1K after | |
| Sep 7, 2022 (view filing) | Sep 2 | 5 days | King RobertChief Development Officer | SSale | −176 | $10.62 | −$1.87K | 0.0%529.3K after | |
| Jun 6, 2022 (view filing) | Jun 2 | 4 days | King RobertChief Development Officer | SSale | −177 | $8.71 | −$1.54K | 0.0%529.5K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | King RobertChief Development Officer | SSale | −287 | $15.57 | −$4.47K | −0.1%528.4K after | |
| Dec 14, 2021 (view filing) | Dec 10-13 | 4 days | Suliman ShehnaazPresident and COO | SSale | −150.0K | $21.50 | −$3.23M | −59.4%102.6K after | 4 lots |
| Dec 10, 2021 (view filing) | Dec 8-9 | 2 days | Suliman ShehnaazPresident and COO | SSale | −150.0K | $22.81 | −$3.42M | −59.4%102.6K after | 4 lots |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | King RobertChief Development Officer | SSale | −250 | $20.09 | −$5.02K | 0.0%528.7K after | |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −110.0K | $25.00 | −$2.75M | −5.3%1.97M after | 2 lots |
| Nov 10, 2021 (view filing) | Nov 8-9 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −200.0K | $25.00 | −$5.00M | −23.5%652.5K after | 8 lots |
| Nov 8, 2021 (view filing) | Nov 4-5 | 4 days | Rosenthal ArnonChief Executive Officer | SSale | −200.0K | $25.00 | −$5.00M | −22.7%682.5K after | 8 lots |
| Sep 23, 2021 (view filing) | Sep 22-23 | 1 day | Rosenthal ArnonChief Executive Officer | SSale | −109.6K | $25.31 | −$2.77M | −4.5%2.30M after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Rosenthal ArnonChief Executive Officer | SSale | −200.0K | $25.96 | −$5.19M | −7.7%2.41M after | 4 lots |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Paul RobertChief Medical Officer | SSale | −22.9K | $27.18 | −$623.7K | −8.9%234.3K after | 2 lots |
| Aug 9, 2021 (view filing) | Jul 2-Aug 5 | 38 daysLate | Scheller Richard HDirector | SSale | −66.2K | $28.20 | −$1.87M | −100.0%0 after | 3 lots |
| Jul 8, 2021 (view filing) | Jul 6-7 | 2 days | Paul RobertChief Medical Officer | SSale | −59.7K | $38.00 | −$2.27M | −20.3%234.3K after | 9 lots |
| Jul 7, 2021 (view filing) | Jul 2-6 | 5 days | Yu CalvinVice President, Finance | SSale | −114.2K | $32.80 | −$3.74M | −59.8%76.7K after | 3 lots |
| Jul 7, 2021 (view filing) | Jul 2 | 5 days | King RobertChief Development Officer | SSale | −60.0K | $31.14 | −$1.87M | −10.3%522.3K after | |
| Jul 6, 2021 (view filing) | Jul 1-2 | 5 days | Paul RobertChief Medical Officer | SSale | −56.7K | $26.94 | −$1.53M | −19.5%234.3K after | 2 lots |